BioNxt Solutions MCTO Revoked by British Columbia Securities Commission

BioNxt Solutions Inc. has announced the revocation of the temporary management cease trade order by the British Columbia Securities Commission. The order, issued on May 1, 2025, under National Policy 12-203, was lifted following the successful completion of the company's annual filings. These filings, for the year ending December 31, 2024, include audited financial statements and management discussions. They are available under BioNxt's profile on SEDAR+.

The revocation allows management to resume trading the company's securities. BioNxt Solutions continues its focus on innovative drug delivery technologies and its main operations are concentrated in Europe. The company is listed on multiple exchanges including the Canadian Securities Exchange, OTC Markets, and in Germany.